Candida albicans biofilm dispersion as a key step during candidiasis

白色念珠菌生物膜分散是念珠菌病的关键步骤

基本信息

  • 批准号:
    7847613
  • 负责人:
  • 金额:
    $ 18.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-22 至 2012-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Candidiasis now represents the third most frequent nosocomial infection in hospitals both in the US and worldwide, and C. albicans remains the most frequent causative agent of candidiasis. Unfortunately these infections carry unacceptably high mortality rates. Candidiasis is often associated with biofilm formation and once established, biofilms have the potential to initiate or prolong infections by providing a safe sanctuary from which organisms can invade local tissue, seed new infection sites and resist eradication efforts. Biofilm accumulation results from the balance of attachment, growth, and dispersion processes. Without any question, of these phenomena, the least understood is biofilm dispersion. In the case of C. albicans this is particularly worrisome because biofilm dispersion is the step that represents the main culprit associated with life-threatening clinical infections in susceptible patients: it is precisely the detached cells that are responsible for septicemia and for dissemination to target organs prior to the establishment of invasive disease. Importantly, both of these clinical manifestations (candidemia and systemic invasive candidiasis) are associated with the high morbidity and mortality rates. Therefore, the main objective of the proposed studies is to examine the process of biofilm dispersion. To this end we will: i) identify the environmental signals associated with C. albicans biofilm dispersion, ii) identify the molecular mechanisms involved in biofilm dispersion and iii) analyze the phenotypes of yeast cells dispersed from the biofilm, with special emphasis on adhesive properties, drug resistance and virulence. The proposed research is innovative since it studies biofilms, one of the major paradigms of modern microbiology. Moreover, it focuses on a process, biofilm dispersion, that has largely been ignored in the past by C. albicans investigators. PUBLIC HEALTH RELEVANCE: Biofilm formation has severe consequences for human health. The main idea behind this study is that we need to better understand how C. albicans cells detach or separate from biofilms, since these cells are responsible for the subsequent establishment of infections in different organs. If we prevent this critical step, it may lead to a substantial reduction in morbidity, mortality and extended hospital stay, while simultaneously reducing healthcare costs.
描述(由申请人提供):念珠菌病现在是美国和世界范围内医院中第三大最常见的医院感染,而C。白色念珠菌仍然是念珠菌病最常见的病原体。不幸的是,这些感染的死亡率高得令人无法接受。绦虫病通常与生物膜形成有关,一旦建立,生物膜有可能通过提供安全的避难所来启动或延长感染,生物体可以从该避难所侵入局部组织,播种新的感染部位并抵抗根除努力。生物膜积累是附着、生长和分散过程平衡的结果。毫无疑问,在这些现象中,最不了解的是生物膜分散。在C.白色念珠菌这是特别令人担忧的,因为生物膜分散是代表与易感患者中威胁生命的临床感染相关的主要罪魁祸首的步骤:正是分离的细胞负责败血症和在侵袭性疾病建立之前传播到靶器官。重要的是,这两种临床表现(念珠菌血症和全身侵袭性念珠菌病)与高发病率和死亡率相关。因此,拟议的研究的主要目标是检查生物膜分散的过程。为此,我们将:i)识别与C相关的环境信号。白念珠菌生物膜分散,ii)鉴定生物膜分散中涉及的分子机制,和iii)分析从生物膜分散的酵母细胞的表型,特别强调粘附特性、耐药性和毒力。拟议的研究是创新的,因为它研究生物膜,现代微生物学的主要范式之一。此外,它集中在一个过程,生物膜分散,这在很大程度上被忽视,在过去的C。白色念珠菌研究人员。公共卫生相关性:生物膜的形成对人类健康有严重的后果。这项研究背后的主要思想是,我们需要更好地了解C。白色念珠菌细胞从生物膜上脱落或分离,因为这些细胞负责随后在不同器官中建立感染。如果我们阻止这一关键步骤,可能会导致发病率、死亡率和住院时间的大幅降低,同时降低医疗成本。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Dispersion as an important step in the Candida albicans biofilm developmental cycle.
  • DOI:
    10.1371/journal.ppat.1000828
  • 发表时间:
    2010-03-26
  • 期刊:
  • 影响因子:
    6.7
  • 作者:
    Uppuluri P;Chaturvedi AK;Srinivasan A;Banerjee M;Ramasubramaniam AK;Köhler JR;Kadosh D;Lopez-Ribot JL
  • 通讯作者:
    Lopez-Ribot JL
Go Forth and Colonize: Dispersal from Clinically Important Microbial Biofilms.
  • DOI:
    10.1371/journal.ppat.1005397
  • 发表时间:
    2016-02
  • 期刊:
  • 影响因子:
    6.7
  • 作者:
    Uppuluri P;Lopez-Ribot JL
  • 通讯作者:
    Lopez-Ribot JL
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jose L. Lopez-Ribot其他文献

Protocol optimization for a fast, simple and economical chemical reduction synthesis of antimicrobial silver nanoparticles in non-specialized facilities
  • DOI:
    10.1186/s13104-019-4813-z
  • 发表时间:
    2019-11-27
  • 期刊:
  • 影响因子:
    1.700
  • 作者:
    Roberto Vazquez-Muñoz;M. Josefina Arellano-Jimenez;Fernando D. Lopez;Jose L. Lopez-Ribot
  • 通讯作者:
    Jose L. Lopez-Ribot
Fungal biofilms in human health and disease
人类健康与疾病中的真菌生物膜
  • DOI:
    10.1038/s41579-025-01147-0
  • 发表时间:
    2025-02-05
  • 期刊:
  • 影响因子:
    103.300
  • 作者:
    Gordon Ramage;Ryan Kean;Riina Rautemaa-Richardson;Craig Williams;Jose L. Lopez-Ribot
  • 通讯作者:
    Jose L. Lopez-Ribot
Antifungal therapy of emCandida/em biofilms: Past, present and future
念珠菌生物膜的抗真菌治疗:过去、现在和未来
  • DOI:
    10.1016/j.bioflm.2023.100126
  • 发表时间:
    2023-12-01
  • 期刊:
  • 影响因子:
    4.900
  • 作者:
    Olabayo H. Ajetunmobi;Hamid Badali;Jesus A. Romo;Gordon Ramage;Jose L. Lopez-Ribot
  • 通讯作者:
    Jose L. Lopez-Ribot

Jose L. Lopez-Ribot的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jose L. Lopez-Ribot', 18)}}的其他基金

BSL3 Drug Screening Core
BSL3 药物筛选核心
  • 批准号:
    10363478
  • 财政年份:
    2022
  • 资助金额:
    $ 18.06万
  • 项目类别:
BSL3 Drug Screening Core
BSL3 药物筛选核心
  • 批准号:
    10541228
  • 财政年份:
    2022
  • 资助金额:
    $ 18.06万
  • 项目类别:
High Throughput Screening of Medicines for Malaria Ventures Chemical Libraries to Identify Novel Inhibitors of Candida auris
疟疾药物的高通量筛选帮助化学库鉴定新型耳念珠菌抑制剂
  • 批准号:
    10383652
  • 财政年份:
    2021
  • 资助金额:
    $ 18.06万
  • 项目类别:
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates
筛选基于靶点的再利用文库的抗真菌病原体活性以及主要候选药物的后续临床前开发
  • 批准号:
    10335279
  • 财政年份:
    2019
  • 资助金额:
    $ 18.06万
  • 项目类别:
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates
筛选基于靶点的再利用文库的抗真菌病原体活性以及主要候选药物的后续临床前开发
  • 批准号:
    10320258
  • 财政年份:
    2019
  • 资助金额:
    $ 18.06万
  • 项目类别:
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates
筛选基于靶点的再利用文库的抗真菌病原体活性以及主要候选药物的后续临床前开发
  • 批准号:
    10544529
  • 财政年份:
    2019
  • 资助金额:
    $ 18.06万
  • 项目类别:
Development of novel chemical series of Candida albicans biofilm inhibitors
白色念珠菌生物膜抑制剂新型化学系列的开发
  • 批准号:
    8951343
  • 财政年份:
    2015
  • 资助金额:
    $ 18.06万
  • 项目类别:
Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis
抗新生儿念珠菌病单克隆抗体 (Mab) 生物制剂的开发
  • 批准号:
    8425740
  • 财政年份:
    2013
  • 资助金额:
    $ 18.06万
  • 项目类别:
Targeting virulence against oral candidiasis in HIV/AIDS
针对艾滋病毒/艾滋病口腔念珠菌病的毒力
  • 批准号:
    9234520
  • 财政年份:
    2013
  • 资助金额:
    $ 18.06万
  • 项目类别:
Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis
抗新生儿念珠菌病单克隆抗体 (Mab) 生物制剂的开发
  • 批准号:
    8719015
  • 财政年份:
    2013
  • 资助金额:
    $ 18.06万
  • 项目类别:

相似海外基金

I-Corps: Translation Potential of Peptidic Ensembles as Novel Bio-adhesives
I-Corps:肽整体作为新型生物粘合剂的转化潜力
  • 批准号:
    2409620
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Standard Grant
Architectural design of active adhesives
活性粘合剂的结构设计
  • 批准号:
    2403716
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Standard Grant
Design of non-swellable adhesives for brain surgery using cyclodextrin inclusion polymer
使用环糊精包合物聚合物脑外科不可溶胀粘合剂的设计
  • 批准号:
    23H01718
  • 财政年份:
    2023
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Meta-material adhesives for improved performance and functionalisation of bondlines
超材料粘合剂可提高粘合层的性能和功能化
  • 批准号:
    EP/W019450/1
  • 财政年份:
    2023
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Fellowship
Light-propelled dental adhesives with enhanced bonding capability
具有增强粘合能力的光驱动牙科粘合剂
  • 批准号:
    10741660
  • 财政年份:
    2023
  • 资助金额:
    $ 18.06万
  • 项目类别:
Mag-Cure: A novel method for magnetically induced bonding and de-bonding of thermoset adhesives in the Automotive Industry
Mag-Cure:汽车行业中热固性粘合剂磁感应粘合和脱粘的新方法
  • 批准号:
    10062336
  • 财政年份:
    2023
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Collaborative R&D
DMREF: Accelerating the Design of Adhesives with Nanoscale Control of Thermomechanical Properties
DMREF:通过热机械性能的纳米级控制加速粘合剂的设计
  • 批准号:
    2323317
  • 财政年份:
    2023
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Continuing Grant
Biodegradable, Biocompatible Pressure Sensitive Adhesives
可生物降解、生物相容性压敏粘合剂
  • 批准号:
    10677869
  • 财政年份:
    2022
  • 资助金额:
    $ 18.06万
  • 项目类别:
Poly(glycerol carbonate) pressure sensitive adhesives for the in vivo closure of alveolar pleural fistulae
用于体内闭合肺泡胸膜瘘的聚(甘油碳酸酯)压敏粘合剂
  • 批准号:
    10746743
  • 财政年份:
    2022
  • 资助金额:
    $ 18.06万
  • 项目类别:
Mechanisms of Blood Clot Adhesion and the Design of New Wet Adhesives
血凝块粘附机制及新型湿粘合剂的设计
  • 批准号:
    RGPIN-2018-04918
  • 财政年份:
    2022
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了